Baricitinib is an orally administered inhibitor of JAK kinases 1 and 2 and is commonly used in the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. For patients with rheumatoid arthritis who have not previously used bio-DMARDS drugs, barikantinib can reduce the disease activity.
Baricitinib tablets are prescribed to treat adult patients suffering from moderate to severe rheumatoid arthritis who show loss of response to one or more tumor necrosis factor antagonist treatment schedules.
Baricitinib works by blocking the actions of Janus kinase (JAK) which is involved with the activation of signaling of molecules and the proinflammatory mediators which are found to be responsible for causing autoimmune disorders.
Baricitinib is recommended for use either alone or in combination with methotrexate or with other disease-modifying antirheumatic drugs (DMARDs).
The European medicines agency (EMA) approved baricitinib tablets to use throughout the EU on Feb 13, 2017.
